NIH R01 · 2024
Formulation to Generate Tolerance Towards Type 1 Diabetes
ABSTRACT Currently no cure exists for the autoimmune disease Type 1 diabetes (T1D). The Juvenile Diabetes Research Foundation estimates ~80 individuals are newly diagnosed with the disease, daily. Due to immune-mediated destruction of the insulin-producing β cells, current treatment of T1D is limited to daily exogenous insulin administration. What is needed are immunotherapies that selectively suppress cell autoimmunity for the prevention and treatment of T1D. One approach is the administration of cell autoantigen to suppress and tolerize diabetogenic effector T cells. Importantly, this approach avoids effects on protective immunity seen with other T1D immunotherapies tested in the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.